PET research at OUS

At OUS, three clinical PET/CT scanners are available for clinical studies. The facility is located at three sites within the Division of Radiology and Nuclear Medicine, and provides the framework needed to conduct high-quality PET research. This includes support on study design, post-processing, interpretation and data analyses.

For preclinical PET research, a PET/CT is available in collaboration with IMB, UiO. From Q2 2023, OUS will also host a preclinical PET/MRI facility, which will be part of the Division of Heart-, Lung- and vascular diseases. The preclinical PET/MRI facility will be located at the Department of Comparative Medicine, RH, and hold a state-of-art PET/MRI preclinical scanner funded primarily by the Norwegian Research Counsil on national research infrastructure. 

Details about the PET instrumentation and facilities for PET research at OUS are given in the Instrumentation section. Radiopharmaceuticals are available either through in-house production or via our close collaboration with NMS AS.   


Clinical PET

The clinical PET research facility facilitates: 

  • PET/CT examinations within various fields of biomedical research  
  • Consultation on study design and protocol setup
  • Execution of experiments
  • Data analyses and interpretation of results
Discovery MI PET/CT


  • Discovery MI PET/CT (GE Healthcare)
  • Biograph mCT PET/CT (Siemens Healthineers) 
  • Cardiac and respiratory gating
  • Laser beam system for radiation planning
  • Automated blood sampler for arterial blood sampling 

Data analysis software:

  • Syngo.Via (Siemens Healthineers)
  • AW (GE Healthcare)
  • PMOD (PMOD Technologies)

Preclinical PET (Q2 2023)

The preclinical PET research facility facilitates: 

  • PET/MRI examinations of mice and rats within various fields of biomedical research  
  • Handling of mice and rats used in research 
  • Teaching and instrument-specific training
  • Consultation on study design and protocol setup
  • Advice and guidance for optimal used of PET technology
  • Execution of experiments
  • Data analyses and interpretation of results


Data analysis software:

  • VivoQuant (Invicro)


Clinical PET: 

Following the project meeting an estimate of the total costs of the project will be made. The PET examinations vary considerably in price depending on tracer, protocol, and reprocessing and data collection. 

We either charge a fee for each scan– usually short term project, but for most long term projects we negotiate a price depending on the needs of each project.

Preclinical PET: 

Academic users: 

  • Use of instrument: 600 NOK/hour
  • Supervised use (incl technical assistance): 1000 NOK/hour
  • Additional technical assistance (e.g. for data analysis): 400 NOK/hour

Commercial users: 

  • Use of instrument: 1400 NOK/hour
  • Supervised use (incl technical assistance): 2500 NOK/hour
  • Additional technical assistance (e.g. for data analysis): 1100 NOK/hour


  • Imaging molecular mechanisms of angiogenesis in glioma-associated neovasculature 
  • The Prognostic Value of Advance Image Analysis of 18F-FDG PET/CT in Patients Treated with Resection or Transplantation for Colorectal Liver Metastases
  • Development of new biomarkers using radiomics and artificial intelligence (AI) for the characterization of tumor heterogeneity and disease patterns
  • The use of PET in the characterizations and management of atherosclerotic plaques
  • Effect of immunotherapy on cognitive function
  • Clinical usefulness of advanced image analysis of PET/CT for in vivo characterisation of neuroendocrine carcinomas
  • Linking genetics and protein pathology in Parkinson's disease: α-synuclein and β-amyloid
  • CovaxHead: The characteristics of covid-19 vaccine-related headache in health care personnel.
  • Characterization of bacterial brain abscesses using molecular imaging techniques
  • A novel PET-based prediction platform for myeloma patients Theranostic radiopharmaceuticals for metastatic cancer
  • Amyloid imaging by 18F-Flutemetamol PET/CT and MRI – clinical value and quantitative reference levels
  • Combinatory ImmunoTherapy-2 (Com-IT-2).: A phase 2 randomised study to assess the tolerability and efficacy of immunotherapy combined with extensive radiation for the treatment of stage IV non-small cell lung cancer


Clinical PET/CT: Mona-Elisabeth Rootwelt- Revheim, Dept. of Nuclear Medicine, OUS. E-mail:

Preclinical PET/MRI: Trine Hjørnevik, IEMR, OUS. E-mail:

Open document as PDF: PET research at OUS

Page visits: 124